With the relevance of PSMB5 mutations in relapse of MM patients remaining elusive28, discovering alternate mechanisms potentiating bortezomib resistance are crucial for designing novel therapeutic interventions to treat these malignancies. This evidence concerns the gene PSMB5 and Miyoshi myopathy.